Recent Advances in the Treatment of Schizophrenia:
Increasing Adherence to Optimize Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Alkermes and Otsuka America Pharmaceuticals and Lundbeck

Schizophrenia is a mental illness that takes away a person’s ability to think clearly, manage emotions, make decisions and socialize with others. It is a complex, long-term medical illness, affecting about 2.4 million American adults. Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 30s. The difficulty of diagnosing this illness is compounded by the fact that many people who are diagnosed do not believe they have it. While there is no single physical or lab test that can diagnosis schizophrenia, a health care provider who evaluates the symptoms and the course of a person's illness over six months can help ensure a correct diagnosis. The health care provider must rule out other factors such as brain tumors, possible medical conditions and other psychiatric diagnoses, such as bipolar disorder. As with most diseases, the earlier the disease is diagnosed, the chances of managing the disease will be significantly higher.

There is no cure for schizophrenia thus the goal of treatment is to reduce the symptoms and to decrease the chances of a relapse. Antipsychotic medications are proven effective in treating acute psychosis and reducing the risk of future psychotic episodes. First-generation and second-generation antipsychotics pose different efficacy, risks, and cost while emerging therapies may overcome the side effects such as weight gain, depression, suicide, restlessness, stiffness, tremors, and muscle spasms. Non-pharmacologic forms of therapy, such as psychosocial interventions and electroconvulsive therapy, are also available for patients who do not respond to drug therapy.

Upon Completion of this activity, participants will be able to:

  • Analyze the current evidence and recent clinical data for the available and emerging therapies for the management of schizophrenia based on pharmacological properties

  • Examine the recent changes in the understanding of schizophrenia, including advances in genetics and imaging

  • Evaluate individualized treatment strategies that reflect the individual patient's symptomatic domains, improve adherence, and prevent relapse

  • Identify barriers to care in patients with schizophrenia and develop strategies to counteract them

  • Assess different therapy changes in patients who are unable to tolerate a prescribed treatment

Faculty: Patrick Runnels, MD
Director, Public and Community Psychiatry Fellowship
Director of Ambulatory Psychiatry
University Hospitals
Associate Professor, Department of Psychiatry
Case Western Reserve University School of Medicine


Dr. Runnels has no financial relationships to disclose. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Alkermes and Otsuka America Pharmaceuticals and Lundbeck

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue